Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas
NCT04089449 · View on ClinicalTrials.gov ↗
Study Summary
This is a Phase 1 dose-escalation study of PRT811, a protein arginine N-methyltransferase (PRMT) 5 inhibitor, in subjects with advanced cancers and high-grade gliomas who have exhausted available treatment options. The purpose of this study is to define a safe dose and schedule to be used in subsequent development of PRT811.
Conditions Studied
Interventions
- DRUG PRT811
Study Locations (11)
Colorado
- Sarah Cannon Research Institute at HealthONE — Denver
Connecticut
- Yale- New Haven Hospital- Yale Cancer Center — New Haven
Delaware
- Christiana Care Health Services, Christiana Hospital — Newark
Florida
- Florida Cancer Specialists — Lake Mary
Georgia
- Georgia Cancer Center at Augusta University — Augusta
Illinois
- Northwestern Memorial Hospital — Chicago
Iowa
- University of Iowa Hospitals and Clinics — Iowa City
Missouri
- Washington University School of Medicine - Siteman Cancer Center — St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2019-11-06 |
| Est. Completion | 2023-03-28 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04089449
The ClinicalTrials.gov registry entry for NCT04089449 describes a study currently listed as completed. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Prelude Therapeutics, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention — of which PRT811 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT04089449 reports 11 study locations spanning 11 distinct geographic areas — top geographies include Colorado, Connecticut, Delaware. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT04089449 about?
NCT04089449 is a clinical study titled "A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas". This is a Phase 1 dose-escalation study of PRT811, a protein arginine N-methyltransferase (PRMT) 5 inhibitor, in subjects with advanced cancers and high-grade gliomas who have exhausted available treatment options. The purpose of this study is to define a safe dose and schedule to be used in subsequ...
What is the current status of trial NCT04089449?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 86 participants. The study started on 2019-11-06. Estimated completion is 2023-03-28.
What conditions does trial NCT04089449 study?
This clinical trial studies the following conditions: Advanced Solid Tumor, Recurrent Glioma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT04089449?
The interventions under investigation include: PRT811 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT04089449?
This trial is sponsored by Prelude Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT04089449 being conducted?
This trial has 11 study locations across Colorado, Connecticut, Delaware, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.